Argenx to Buy Forte Biosciences for $2.2 Billion
10 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Argenx to Buy Forte Biosciences for $2.2 Billion" is generating significant coverage in the Business category, with 10 articles from 10 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Yahoo Finance, STAT, GlobeNewswire and Investing.com. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 109d ago.
Quick answers
Why is "Argenx to Buy Forte Biosciences for $2.2 Billion" trending?
Because 10 independent news sources published 10 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (10)
- argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline Yahoo Finance · 111d ago
- Argenx to buy autoimmune-focused Forte Biosciences for $2.2B STAT · 112d ago
- argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline GlobeNewswire · 112d ago
- TD Cowen downgrades Forte Biosciences stock rating on Argenx deal Investing.com · 112d ago
- Argenx to acquire Forte Biosciences for $2.2B Axios · 112d ago
- TD Cowen downgrades Forte Biosciences stock rating on Argenx deal By Investing.com Investing.com Canada · 112d ago
- argenx to buy Forte Bio for $2.2B in immunology push FirstWord Pharma · 112d ago
- Argenx to pick up autoimmune biotech Forte Biosciences for $2.2B Endpoints News · 112d ago
- Argenx acquires Forte for $2.2B to get hands on phase 2-stage vitiligo drug Fierce Biotech · 112d ago
- Argenx to Buy Forte Biosciences for $2.2 Billion WSJ · 112d ago
Topics
Related trends
Argenx to acquire Unnatural Products in deal worth up to $1.15B
Argenx agrees to acquire Unnatural Products for up to $1.15 billion, betting on AI-guided macrocycle technology to expand oral peptide drug development.
Best Buy's Black Friday Event Begins With Sitewide Savings on Apple, TVs, More
Best Buy launches its early Black Friday event with sitewide discounts on Apple products, Google devices, and TVs.
Best Buy's Early Black Friday Sale is Now Live, Including Deals on Gaming, Tech, and More
Best Buy launches its 2026 Black Friday sale early with deep discounts on Apple, Dyson, Bose and gaming gear across multiple product categories.
Google Plans to Spend $17 Billion on Wyoming Data Center
Google commits to spending $17 billion on artificial intelligence data center infrastructure in Wyoming.
Hackers Paid $15 to Drain $2.5 Billion From Binance in One Hit
A massive cryptocurrency heist involving Binance draws global attention as outlets report staggering financial losses and industry security concerns.
Exclusive | AstraZeneca Made $10 Billion Offer for Rhythm Pharmaceuticals
AstraZeneca reportedly made a $10 billion acquisition offer for obesity drugmaker Rhythm Pharmaceuticals.